content: <HTML>
  <HEAD>
       <TITLE></TITLE>
  </HEAD>
  <BODY STYLE="font: 10pt Times New Roman, Times, Serif">
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>As filed with the Securities and Exchange Commission
  on December 19, 2024</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Registration No. 333-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></P>
  
  <!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B></B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES </B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM S-8 </B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REGISTRATION STATEMENT </B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>UNDER </I></B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>THE SECURITIES ACT OF 1933</I></B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>&nbsp;</I></B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INMED PHARMACEUTICALS INC. </B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Exact name of registrant as specified in its
  charter)</B></P>
  
  <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR>
      <TD STYLE="vertical-align: top; border-bottom: black 1.5pt solid; font-size: 10pt; text-align: center; width: 50%"><FONT STYLE="font-size: 10pt"><B>British Columbia </B></FONT></TD>
      <TD STYLE="vertical-align: bottom; padding-bottom: 1.5pt; font-size: 10pt; width: 1%">&nbsp;</TD>
      <TD STYLE="vertical-align: top; border-bottom: black 1.5pt solid; font-size: 10pt; text-align: center; width: 49%"><FONT STYLE="font-size: 10pt"><B>98-1428279</B></FONT></TD></TR>
    <TR>
      <TD STYLE="vertical-align: top">
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(State or other jurisdiction of</B></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>incorporation or organization)</B>&nbsp;</P></TD>
      <TD STYLE="vertical-align: bottom; font-size: 10pt">&nbsp;</TD>
      <TD STYLE="vertical-align: top">
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(I.R.S Employer</B></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Identification No.)</B>&nbsp;</P></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Suite 1445 - 885 W. Georgia Street</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Vancouver, B.C. V6C 3E8</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Canada</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Telephone: (604) 669-7207</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Address, including zip code and telephone number,
  including area code, of registrant&rsquo;s principal executive offices)</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>InMed Pharmaceuticals Inc. Amended 2017 Stock
  Option Plan</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Full title of the plan) </B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Registered Agent Solutions, Inc.</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>1100 H Street NW</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Suite 840</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, DC 20005</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Telephone: (888) 705-7274</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Name, address, including zip code, and telephone
  number, including area code, of agent for service)</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>Copies to: </I></B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>&nbsp;</I></B></P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR STYLE="vertical-align: top">
      <TD STYLE="padding-right: 5.65pt; padding-left: 5.65pt; width: 50%">
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Eric A. Adams</B></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Chief Executive Officer</B></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>InMed Pharmaceuticals Inc.</B></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Suite 1445 - 885 W. Georgia Street</B></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Vancouver, B.C. V6C 3E8</B></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Canada</B></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Telephone: (604) 669-7207</B></P></TD>
      <TD STYLE="padding-right: 5.65pt; padding-left: 5.65pt; width: 50%">
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Jared D. Kaplan, Esq.</B></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Norton Rose Fulbright US LLP </B></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>1045 W. Fulton Market, Ste 1200</B></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Chicago, IL 60607</B></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Telephone: (312) 964-7800</B></P></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant is a large accelerated
  filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definition of &ldquo;large
  accelerated filer,&rdquo; &ldquo;accelerated filer,&rdquo; &ldquo;smaller reporting company&rdquo; and &ldquo;emerging growth company&rdquo;
  in in Rule 12b-2 of the Exchange Act.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR STYLE="vertical-align: bottom">
      <TD STYLE="width: 40%"><FONT STYLE="font-size: 10pt">Large accelerated filer</FONT></TD>
      <TD STYLE="width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
      <TD STYLE="width: 40%"><FONT STYLE="font-size: 10pt">Accelerated filer</FONT></TD>
      <TD STYLE="width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD></TR>
    <TR STYLE="vertical-align: bottom">
      <TD><FONT STYLE="font-size: 10pt">Non-accelerated filer</FONT></TD>
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</FONT></TD>
      <TD><FONT STYLE="font-size: 10pt">Smaller reporting company</FONT></TD>
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</FONT></TD></TR>
    <TR STYLE="vertical-align: bottom">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD><FONT STYLE="font-size: 10pt">Emerging growth company</FONT></TD>
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If an emerging growth company, indicate by check mark if the registrant
  has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
  to Section 7(a)(2)(B) of the Securities Act. <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <!-- Field: Page; Sequence: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXPLANATORY NOTE</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The purpose of this Registration
  Statement on Form S-8 (this &ldquo;Registration Statement&rdquo;) is to register an additional 60,000 common shares, no par value (the
  &ldquo;Common Shares&rdquo;), of InMed Pharmaceuticals Inc. (the &ldquo;Company&rdquo;), for allotment under the InMed Pharmaceuticals
  Inc. Amended 2017 Stock Option Plan (the &ldquo;2017 Stock Option Plan&rdquo;). Effective December 18, 2024, the board of directors of
  the Company approved the reservation of an additional 60,000 Common Shares for allotment under the 2017 Stock Option Plan.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On November 14, 2024, the Company effected a one-for-twenty (1-for-20)
  reverse stock split of the Company&rsquo;s issued and outstanding Common Shares (the &ldquo;2024 Reverse Stock Split&rdquo;). As a result
  of the 2024 Reverse Stock Split, every twenty Common Shares issued and outstanding as of November 14, 2024 were combined into one Common
  Share. The number of Common Shares issuable pursuant to the 2017 Stock Option Plan were also adjusted proportionally as a result of the
  2024 Reverse Stock Split. The 2024 Reverse Stock Split resulted in the number of issued and outstanding Common Shares being reduced from
  14,361,550 to approximately 718,078 Common Shares on a non-diluted basis, and each shareholder held the same percentage of Common Shares
  outstanding immediately after the 2024 Reverse Stock Split as such shareholder held immediately prior to the 2024 Reverse Stock Split.
  As previously reported by the Company, the Company additionally conducted a one-for-twenty five (1-for-25) reverse stock split of the
  Company&rsquo;s issued and outstanding Common Shares effective on September 7, 2022 (the &ldquo;2022 Reverse Stock Split&rdquo; and together
  with the 2024 Reverse Stock Split, the &ldquo;Share Consolidations&rdquo;). The number of Common Shares represented herein, including
  in this Explanatory Note, reflect the completion of the Share Consolidations.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In accordance with General
  Instruction E of Form S-8 under the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;), the contents of (i) the Company&rsquo;s
  Registration Statement on Form S-8 (File No. 333-253912), filed with the Securities and Exchange Commission (the &ldquo;Commission&rdquo;)
  on March 5, 2021, to register 2,088 Common Shares for issuance pursuant to the 2017 Stock Option Plan, as amended, (ii) the Company&rsquo;s
  Registration Statement on Form S-8 (File No. 333-260323), filed with the Commission on October 18, 2021, to register an additional 1,600
  Common Shares for issuance pursuant to the 2017 Stock Option Plan, as amended, (iii) the Company&rsquo;s Registration Statement on Form
  S-8 (File No. 333-268356), filed with the Commission on November 14, 2022, to register an additional 4,000 Common Shares for issuance
  pursuant to the 2017 Stock Option Plan, and (iv) the Company&rsquo;s Registration Statement on Form S-8 (File No. 333-276212), filed with
  the Commission on December 22, 2023, to register an additional 35,000 Common Shares for issuance pursuant to the 2017 Stock Option Plan,
  are each incorporated herein by reference, except to the extent supplemented, amended and superseded by the information set forth herein.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  
  <!-- Field: Page; Sequence: 2 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PART II</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
  </B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 3. Incorporation of Documents by Reference. </B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Except to the extent that information is deemed furnished and not filed
  pursuant to securities laws and regulations, the following documents, which have been previously filed with the Commission, are incorporated
  by reference into this Registration Statement:</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our
                                              Annual Report on <A HREF="https://www.sec.gov/Archives/edgar/data/1728328/000121390024082843/ea0214241-10k_inmed.htm">Form 10-K</A> for the fiscal year ended June 30, 2024, filed with the Commission
                                              on September 30, 2024;</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our
                                              Definitive Proxy Statement on <A HREF="https://www.sec.gov/Archives/edgar/data/1728328/000121390024091222/ea0218812-01.htm">Schedule 14A</A>, filed with the Commission on October 28, 2024;</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our
                                              Quarterly Report on <A HREF="https://www.sec.gov/Archives/edgar/data/1728328/000121390024098445/ea0219774-10q_inmed.htm">Form 10-Q</A> for the quarter ended September 30, 2024, filed with the Commission
                                              on November 14, 2024;</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our Current Reports on Form 8-K, filed with the Commission on <A HREF="https://www.sec.gov/Archives/edgar/data/1728328/000101376224002578/ea0210292-8k_inmed.htm">July
                                                                                               30, 2024</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1728328/000121390024071061/ea0211922-8k_inmed.htm">August 20,
                                                                                               2024</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1728328/000121390024071386/ea0212056-8k_inmed.htm">August 21, 2024</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1728328/000121390024080662/ea0215298-8k_inmed.htm">September
                                                                                               20, 2024</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1728328/000121390024082247/ea0215833-8k_inmed.htm">September 26,
                                                                                               2024</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1728328/000121390024083203/ea0216150-8k_inmed.htm">September 30,
                                                                                               2024</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1728328/000121390024089887/ea0218323-8k_inmed.htm">October 23, 2024</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1728328/000121390024090365/ea0218583-8k_inmed.htm">October
                                                                                               24, 2024</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1728328/000121390024091172/ea0218824-8k_inmed.htm">October 28,
                                                                                               2024</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1728328/000121390024094349/ea0220029-8k_inmed.htm">November 5, 2024</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1728328/000121390024096025/ea0220578-8k_inmed.htm">November
                                                                                               12, 2024</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1728328/000121390024098655/ea0221397-8k_inmed.htm">November 15,
                                                                                               2024</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1728328/000121390024100527/ea0222020-8k_inmed.htm">November 20, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1728328/000121390024109891/ea0225022-8k_inmed.htm">December
                                                                                               18, 2024</A> and <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1728328/000121390024110429/ea0225311-8k_inmed.htm" STYLE="-sec-extract: exhibit">December 19, 2024</A>; and</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the description of our common
  shares in our Registration Statement on&nbsp;<A HREF="https://www.sec.gov/Archives/edgar/data/1728328/000119312520285837/d72199d8a12b.htm">Form 8-A</A>&nbsp;filed with the Commission on November 5, 2020, including any subsequent amendment
  thereto filed for the purpose of updating such description.</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Except to the extent that information is deemed
  furnished and not filed pursuant to securities laws and regulations, all documents filed by the Company with the Commission pursuant to
  Sections 13(a), 13(c), 14 and 15(d) of the Securities Exchange Act of 1934, as amended, after the date of this Registration Statement
  and prior to the filing of a post-effective amendment that (i) indicates that all securities offered under this Registration Statement
  have been sold, or (ii) deregisters all securities then remaining unsold under this Registration Statement, shall be deemed to be incorporated
  by reference into this Registration Statement and to be a part of this Registration Statement from the date of filing of such documents.
  In no event, however, will any information that we disclose under Item 2.02 or Item 7.01 (and any related exhibits) of any Current Report
  on Form 8-K that we may from time to time furnish to the Commission be incorporated by reference into, or otherwise become a part of,
  this Registration Statement.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For purposes of this Registration Statement, any
  statement contained in a document incorporated or deemed to be incorporated herein by reference shall be deemed to be modified or superseded
  to the extent that a statement contained herein or in any subsequently filed document which also is or is deemed to be incorporated herein
  by reference modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified
  or superseded, to constitute a part of this Registration Statement.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  
  <!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></FONT></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR STYLE="vertical-align: top">
      <TD STYLE="font-size: 10pt; width: 0.75in"><FONT STYLE="font-size: 10pt"><B>ITEM 8.</B></FONT></TD>
      <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Exhibits. </B></FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR STYLE="vertical-align: bottom">
      <TD STYLE="border-bottom: black 1.5pt solid; white-space: nowrap; text-align: left; width: 12%"><FONT STYLE="font-size: 10pt"><B>Exhibit&nbsp;No.</B></FONT></TD>
      <TD STYLE="padding-bottom: 1.5pt; width: 1%">&nbsp;</TD>
      <TD STYLE="white-space: nowrap; border-bottom: black 1.5pt solid; text-align: center; width: 87%"><FONT STYLE="font-size: 10pt"><B>Exhibit
      Description</B></FONT></TD></TR>
    <TR STYLE="background-color: #CCEEFF">
      <TD STYLE="white-space: nowrap; vertical-align: top; text-align: left"><FONT STYLE="font-size: 10pt">4.1</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1728328/000119312520174157/d904092dex31.htm">Amended
      and Restated Articles (incorporated by reference to Exhibit 3.1 to the Registrant&rsquo;s Registration Statement on Form S-1 (File
      No. 333-239319), filed on June 19, 2020).</A></FONT></TD></TR>
    <TR STYLE="background-color: white">
      <TD STYLE="white-space: nowrap; vertical-align: top; text-align: left">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD></TR>
    <TR STYLE="background-color: #CCEEFF">
      <TD STYLE="white-space: nowrap; vertical-align: top; text-align: left"><FONT STYLE="font-size: 10pt">4.2</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1728328/000121390021013661/ea136989ex4-2_inmedpharma.htm">InMed
      Pharmaceuticals Inc. Amended 2017 Stock Option Plan (incorporated by reference to Exhibit 4.2 to the Registrant&rsquo;s Registration
      Statement on Form S-8 (File No. 333-253912) filed on March 5, 2021).</A></FONT></TD></TR>
    <TR STYLE="background-color: white">
      <TD STYLE="white-space: nowrap; vertical-align: top; text-align: left">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD></TR>
    <TR STYLE="background-color: #CCEEFF">
      <TD STYLE="white-space: nowrap; vertical-align: top; text-align: left"><FONT STYLE="font-size: 10pt">4.3</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1728328/000121390021013661/ea136989ex4-3_inmedpharma.htm">Form
      of Stock Option Agreement pursuant to InMed Pharmaceuticals Inc. Amended 2017 Stock Option Plan (incorporated by reference to Exhibit
      4.3 to the Registrant&rsquo;s Registration Statement on Form S-8 (File No. 333-253912) filed on March 5, 2021).</A></FONT></TD></TR>
    <TR STYLE="background-color: white">
      <TD STYLE="white-space: nowrap; vertical-align: top; text-align: left">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD></TR>
    <TR STYLE="background-color: #CCEEFF">
      <TD STYLE="white-space: nowrap; vertical-align: top; text-align: left"><FONT STYLE="font-size: 10pt">4.4</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1728328/000121390021036589/ea144036ex4-3_inmedpha.htm">Form
      of Specific Common Share Certificate (incorporated by reference to Exhibit 4.3 to the Company&rsquo;s Form S-1 filed on July 13,
      2021).</A></FONT></TD></TR>
    <TR STYLE="background-color: white">
      <TD STYLE="text-align: left">&nbsp;</TD>
      <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
    <TR STYLE="background-color: #CCEEFF">
      <TD STYLE="white-space: nowrap; vertical-align: top; text-align: left"><FONT STYLE="font-size: 10pt">5.1*</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top; text-align: justify"><A HREF="ea022524901ex5-1_inmed.htm"><FONT STYLE="font-size: 10pt">Opinion of
      Norton Rose Fulbright Canada LLP regarding legality of securities being registered.</FONT></A></TD></TR>
    <TR STYLE="background-color: white">
      <TD STYLE="white-space: nowrap; vertical-align: top; text-align: left">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD></TR>
    <TR STYLE="background-color: #CCEEFF">
      <TD STYLE="white-space: nowrap; vertical-align: top; text-align: left"><FONT STYLE="font-size: 10pt">23.1*</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top; text-align: justify"><A HREF="ea022524901ex23-1_inmed.htm">Consent of Marcum LLP</A></TD></TR>
    <TR STYLE="background-color: white">
      <TD STYLE="text-align: left">&nbsp;</TD>
      <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
    <TR STYLE="background-color: #CCEEFF">
      <TD STYLE="white-space: nowrap; vertical-align: top; text-align: left"><FONT STYLE="font-size: 10pt">23.2*</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top; text-align: justify"><A HREF="ea022524901ex5-1_inmed.htm"><FONT STYLE="font-size: 10pt">Consent of
      Norton Rose Fulbright Canada LLP (contained in Exhibit 5.1).</FONT></A></TD></TR>
    <TR STYLE="background-color: white">
      <TD STYLE="text-align: left">&nbsp;</TD>
      <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
    <TR STYLE="background-color: #CCEEFF">
      <TD STYLE="white-space: nowrap; vertical-align: top; text-align: left"><FONT STYLE="font-size: 10pt">24.1*</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt"><A HREF="#a_001">Power of Attorney (included as
      part of signature page to this Registration Statement).</A></FONT></TD></TR>
    <TR STYLE="background-color: white">
      <TD STYLE="text-align: left">&nbsp;</TD>
      <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
    <TR STYLE="background-color: #CCEEFF">
      <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">107.1*</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><A HREF="ea022524901ex-fee_inmed.htm">Calculation of Filing Fee Tables</A></FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">*</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Filed herewith.</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.75pt">&nbsp;</P>
  
  <!-- Field: Page; Sequence: 4; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
  of the Securities Act, InMed Pharmaceuticals Inc., certifies that it has reasonable grounds to believe that it meets all of the requirements
  for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized,
  in the City of Vancouver, British Columbia, Canada, on December 19, 2024.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>INMED PHARMACEUTICALS INC.</B></FONT></TD></TR>
    <TR>
      <TD STYLE="width: 60%">&nbsp;</TD>
      <TD STYLE="width: 4%">&nbsp;</TD>
      <TD STYLE="width: 36%">&nbsp;</TD></TR>
    <TR>
      <TD>&nbsp;</TD>
      <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
      <TD STYLE="vertical-align: top; border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt">/s/ Eric A. Adams</FONT></TD></TR>
    <TR>
      <TD>&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Eric A. Adams </FONT></TD></TR>
    <TR>
      <TD>&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">President and Chief Executive Officer</FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_001"></A>POWER OF ATTORNEY</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each person whose signature
  appears below, the undersigned officers and directors of InMed Pharmaceuticals Inc., hereby severally constitute and appoint Eric A. Adams
  and Netta Jagpal, and each of them singly (with full power to each of them to act alone), his or her true and lawful attorneys-in-fact
  and agents, with full power of substitution and resubstitution in each of them for him (or her) and in his (or her) name, place and stead,
  and in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and
  to file the same, with all exhibits thereto and other documents in connection therewith, with the Commission, granting unto said attorneys-in-fact
  and agents, and each of them, full power and authority to do and perform each and every act and thing requisite or necessary to be done
  in and about the premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all
  that said attorneys-in-fact and agents or any of them, or their or his (or her) substitute or substitutes, may lawfully do or cause to
  be done by virtue hereof.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
  of the Securities Act, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated
  on December 19, 2024.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR STYLE="vertical-align: bottom">
      <TD STYLE="white-space: nowrap; border-bottom: black 1.5pt solid; text-align: center; width: 40%"><FONT STYLE="font-size: 10pt"><B>Name</B></FONT></TD>
      <TD STYLE="padding-bottom: 1.5pt; width: 1%">&nbsp;</TD>
      <TD STYLE="white-space: nowrap; border-bottom: black 1.5pt solid; text-align: center; width: 59%"><FONT STYLE="font-size: 10pt"><B>Title</B></FONT></TD></TR>
    <TR>
      <TD>&nbsp;</TD>
      <TD COLSPAN="2">&nbsp;</TD></TR>
    <TR>
      <TD STYLE="vertical-align: top; border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt">/s/ Eric A. Adams</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">President, Chief Executive Officer and Director</FONT></TD></TR>
    <TR>
      <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Eric A. Adams </FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">(principal executive officer) </FONT></TD></TR>
    <TR>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
    <TR>
      <TD STYLE="vertical-align: top; border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt">/s/ Netta Jagpal</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Chief Financial Officer</FONT></TD></TR>
    <TR>
      <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Netta Jagpal</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">(principal financial officer and principal accounting officer) </FONT></TD></TR>
    <TR>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
    <TR>
      <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt">/s/ Janet Grove </FONT></TD>
      <TD>&nbsp;</TD>
      <TD><FONT STYLE="font-size: 10pt">Director</FONT></TD></TR>
    <TR>
      <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Janet Grove </FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
    <TR>
      <TD>&nbsp;</TD>
      <TD COLSPAN="2">&nbsp;</TD></TR>
    <TR>
      <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt">/s/ Bryan Baldasare</FONT></TD>
      <TD>&nbsp;</TD>
      <TD><FONT STYLE="font-size: 10pt">Director</FONT></TD></TR>
    <TR>
      <TD><FONT STYLE="font-size: 10pt">Bryan Baldasare</FONT></TD>
      <TD COLSPAN="2">&nbsp;</TD></TR>
    <TR>
      <TD>&nbsp;</TD>
      <TD COLSPAN="2">&nbsp;</TD></TR>
    <TR>
      <TD STYLE="vertical-align: top; border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt">/s/ Andrew Hull</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Director</FONT></TD></TR>
    <TR>
      <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Andrew Hull </FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
    <TR>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
    <TR>
      <TD STYLE="vertical-align: top; border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt">/s/ Nicole Lemerond </FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Director</FONT></TD></TR>
    <TR>
      <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Nicole Lemerond </FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>
  
  <!-- Field: Page; Sequence: 5; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AUTHORIZED REPRESENTATIVE</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements to Section 6(a) of
  the Securities Act of 1933, the undersigned has signed this registration statement solely in the capacity of the duly authorized representative
  of InMed Pharmaceuticals Inc. in the United States on December 19, 2024.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR>
      <TD STYLE="width: 60%">&nbsp;</TD>
      <TD STYLE="vertical-align: top; width: 4%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
      <TD STYLE="vertical-align: top; border-bottom: black 1.5pt solid; width: 36%"><FONT STYLE="font-size: 10pt">/s/ Andrew Hull</FONT></TD></TR>
    <TR>
      <TD>&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Andrew Hull</FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>
  
  <!-- Field: Page; Sequence: 6; Options: Last -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></FONT></P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>
  
  </BODY>
  </HTML>
metadata_documents: [{"type": "S-8", "sequence": "1", "filename": "ea0225249-s8_inmedpharma.htm", "description": "REGISTRATION STATEMENT", "secsgml_size_bytes": 44965}]
metadata_filer: {"company-data": {"conformed-name": "InMed Pharmaceuticals Inc.", "cik": "0001728328", "assigned-sic": "2834", "organization-name": "03 Life Sciences", "irs-number": "000000000", "state-of-incorporation": "A1", "fiscal-year-end": "0630"}, "filing-values": {"form-type": "S-8", "act": "33", "file-number": "333-283951", "film-number": "241565014"}, "business-address": {"street1": "1445-885 WEST GEORGIA ST.", "city": "VANCOUVER", "state": "A1", "zip": "V6C 3E8", "phone": "(604) 669-7207"}, "mail-address": {"street1": "1445-885 WEST GEORGIA ST.", "city": "VANCOUVER", "state": "A1", "zip": "V6C 3E8"}}
text: As filed with the Securities and Exchange Commission
  on December 19, 2024
  Registration No. 333-
  UNITED STATES
  SECURITIES AND EXCHANGE COMMISSION
  Washington, D.C. 20549
  FORM S-8
  REGISTRATION STATEMENT
  UNDER
  THE SECURITIES ACT OF 1933
  INMED PHARMACEUTICALS INC.
  (Exact name of registrant as specified in its
  charter)
  British Columbia
  98-1428279
  (State or other jurisdiction of
  incorporation or organization)
  (I.R.S Employer
  Identification No.)
  Suite 1445 - 885 W. Georgia Street
  Vancouver, B.C. V6C 3E8
  Canada
  Telephone: (604) 669-7207
  (Address, including zip code and telephone number,
  including area code, of registrant's principal executive offices)
  InMed Pharmaceuticals Inc. Amended 2017 Stock
  Option Plan
  (Full title of the plan)
  Registered Agent Solutions, Inc.
  1100 H Street NW
  Suite 840
  Washington, DC 20005
  Telephone: (888) 705-7274
  (Name, address, including zip code, and telephone
  number, including area code, of agent for service)
  Copies to:
  Eric A. Adams
  Chief Executive Officer
  InMed Pharmaceuticals Inc.
  Suite 1445 - 885 W. Georgia Street
  Vancouver, B.C. V6C 3E8
  Canada
  Telephone: (604) 669-7207
  Jared D. Kaplan, Esq.
  Norton Rose Fulbright US LLP
  1045 W. Fulton Market, Ste 1200
  Chicago, IL 60607
  Telephone: (312) 964-7800
  Indicate by check mark whether the registrant is a large accelerated
  filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definition of "large
  accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company"
  in in Rule 12b-2 of the Exchange Act.
  Large accelerated filer
  ☐
  Accelerated filer
  ☐
  Non-accelerated filer
  ☒
  Smaller reporting company
  ☒
  Emerging growth company
  ☒
  If an emerging growth company, indicate by check mark if the registrant
  has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
  to Section 7(a)(2)(B) of the Securities Act.
  ☐
  EXPLANATORY NOTE
  The purpose of this Registration
  Statement on Form S-8 (this "Registration Statement") is to register an additional 60,000 common shares, no par value (the
  "Common Shares"), of InMed Pharmaceuticals Inc. (the "Company"), for allotment under the InMed Pharmaceuticals
  Inc. Amended 2017 Stock Option Plan (the "2017 Stock Option Plan"). Effective December 18, 2024, the board of directors of
  the Company approved the reservation of an additional 60,000 Common Shares for allotment under the 2017 Stock Option Plan.
  On November 14, 2024, the Company effected a one-for-twenty (1-for-20)
  reverse stock split of the Company's issued and outstanding Common Shares (the "2024 Reverse Stock Split"). As a result
  of the 2024 Reverse Stock Split, every twenty Common Shares issued and outstanding as of November 14, 2024 were combined into one Common
  Share. The number of Common Shares issuable pursuant to the 2017 Stock Option Plan were also adjusted proportionally as a result of the
  2024 Reverse Stock Split. The 2024 Reverse Stock Split resulted in the number of issued and outstanding Common Shares being reduced from
  14,361,550 to approximately 718,078 Common Shares on a non-diluted basis, and each shareholder held the same percentage of Common Shares
  outstanding immediately after the 2024 Reverse Stock Split as such shareholder held immediately prior to the 2024 Reverse Stock Split.
  As previously reported by the Company, the Company additionally conducted a one-for-twenty five (1-for-25) reverse stock split of the
  Company's issued and outstanding Common Shares effective on September 7, 2022 (the "2022 Reverse Stock Split" and together
  with the 2024 Reverse Stock Split, the "Share Consolidations"). The number of Common Shares represented herein, including
  in this Explanatory Note, reflect the completion of the Share Consolidations.
  In accordance with General
  Instruction E of Form S-8 under the Securities Act of 1933, as amended (the "Securities Act"), the contents of (i) the Company's
  Registration Statement on Form S-8 (File No. 333-253912), filed with the Securities and Exchange Commission (the "Commission")
  on March 5, 2021, to register 2,088 Common Shares for issuance pursuant to the 2017 Stock Option Plan, as amended, (ii) the Company's
  Registration Statement on Form S-8 (File No. 333-260323), filed with the Commission on October 18, 2021, to register an additional 1,600
  Common Shares for issuance pursuant to the 2017 Stock Option Plan, as amended, (iii) the Company's Registration Statement on Form
  S-8 (File No. 333-268356), filed with the Commission on November 14, 2022, to register an additional 4,000 Common Shares for issuance
  pursuant to the 2017 Stock Option Plan, and (iv) the Company's Registration Statement on Form S-8 (File No. 333-276212), filed with
  the Commission on December 22, 2023, to register an additional 35,000 Common Shares for issuance pursuant to the 2017 Stock Option Plan,
  are each incorporated herein by reference, except to the extent supplemented, amended and superseded by the information set forth herein.
  PART II
  INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
  Item 3. Incorporation of Documents by Reference.
  Except to the extent that information is deemed furnished and not filed
  pursuant to securities laws and regulations, the following documents, which have been previously filed with the Commission, are incorporated
  by reference into this Registration Statement:
  ●
  our
                                              Annual Report on
  Form 10-K
  for the fiscal year ended June 30, 2024, filed with the Commission
                                              on September 30, 2024;
  ●
  our
                                              Definitive Proxy Statement on
  Schedule 14A
  , filed with the Commission on October 28, 2024;
  ●
  our
                                              Quarterly Report on
  Form 10-Q
  for the quarter ended September 30, 2024, filed with the Commission
                                              on November 14, 2024;
  ●
  our Current Reports on Form 8-K, filed with the Commission on
  July
                                                                                               30, 2024
  ,
  August 20,
                                                                                               2024
  ,
  August 21, 2024
  ,
  September
                                                                                               20, 2024
  ,
  September 26,
                                                                                               2024
  ,
  September 30,
                                                                                               2024
  ,
  October 23, 2024
  ,
  October
                                                                                               24, 2024
  ,
  October 28,
                                                                                               2024
  ,
  November 5, 2024
  ,
  November
                                                                                               12, 2024
  ,
  November 15,
                                                                                               2024
  ,
  November 20, 2024
  ,
  December
                                                                                               18, 2024
  and
  December 19, 2024
  ; and
  ●
  the description of our common
  shares in our Registration Statement on
  Form 8-A
  filed with the Commission on November 5, 2020, including any subsequent amendment
  thereto filed for the purpose of updating such description.
  Except to the extent that information is deemed
  furnished and not filed pursuant to securities laws and regulations, all documents filed by the Company with the Commission pursuant to
  Sections 13(a), 13(c), 14 and 15(d) of the Securities Exchange Act of 1934, as amended, after the date of this Registration Statement
  and prior to the filing of a post-effective amendment that (i) indicates that all securities offered under this Registration Statement
  have been sold, or (ii) deregisters all securities then remaining unsold under this Registration Statement, shall be deemed to be incorporated
  by reference into this Registration Statement and to be a part of this Registration Statement from the date of filing of such documents.
  In no event, however, will any information that we disclose under Item 2.02 or Item 7.01 (and any related exhibits) of any Current Report
  on Form 8-K that we may from time to time furnish to the Commission be incorporated by reference into, or otherwise become a part of,
  this Registration Statement.
  For purposes of this Registration Statement, any
  statement contained in a document incorporated or deemed to be incorporated herein by reference shall be deemed to be modified or superseded
  to the extent that a statement contained herein or in any subsequently filed document which also is or is deemed to be incorporated herein
  by reference modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified
  or superseded, to constitute a part of this Registration Statement.
  II-
  1
  ITEM 8.
  Exhibits.
  Exhibit No.
  Exhibit
      Description
  4.1
  Amended
      and Restated Articles (incorporated by reference to Exhibit 3.1 to the Registrant's Registration Statement on Form S-1 (File
      No. 333-239319), filed on June 19, 2020).
  4.2
  InMed
      Pharmaceuticals Inc. Amended 2017 Stock Option Plan (incorporated by reference to Exhibit 4.2 to the Registrant's Registration
      Statement on Form S-8 (File No. 333-253912) filed on March 5, 2021).
  4.3
  Form
      of Stock Option Agreement pursuant to InMed Pharmaceuticals Inc. Amended 2017 Stock Option Plan (incorporated by reference to Exhibit
      4.3 to the Registrant's Registration Statement on Form S-8 (File No. 333-253912) filed on March 5, 2021).
  4.4
  Form
      of Specific Common Share Certificate (incorporated by reference to Exhibit 4.3 to the Company's Form S-1 filed on July 13,
      2021).
  5.1*
  Opinion of
      Norton Rose Fulbright Canada LLP regarding legality of securities being registered.
  23.1*
  Consent of Marcum LLP
  23.2*
  Consent of
      Norton Rose Fulbright Canada LLP (contained in Exhibit 5.1).
  24.1*
  Power of Attorney (included as
      part of signature page to this Registration Statement).
  107.1*
  Calculation of Filing Fee Tables
  *
  Filed herewith.
  II-
  2
  SIGNATURES
  Pursuant to the requirements
  of the Securities Act, InMed Pharmaceuticals Inc., certifies that it has reasonable grounds to believe that it meets all of the requirements
  for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized,
  in the City of Vancouver, British Columbia, Canada, on December 19, 2024.
  INMED PHARMACEUTICALS INC.
  By:
  /s/ Eric A. Adams
  Eric A. Adams
  President and Chief Executive Officer
  POWER OF ATTORNEY
  Each person whose signature
  appears below, the undersigned officers and directors of InMed Pharmaceuticals Inc., hereby severally constitute and appoint Eric A. Adams
  and Netta Jagpal, and each of them singly (with full power to each of them to act alone), his or her true and lawful attorneys-in-fact
  and agents, with full power of substitution and resubstitution in each of them for him (or her) and in his (or her) name, place and stead,
  and in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and
  to file the same, with all exhibits thereto and other documents in connection therewith, with the Commission, granting unto said attorneys-in-fact
  and agents, and each of them, full power and authority to do and perform each and every act and thing requisite or necessary to be done
  in and about the premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all
  that said attorneys-in-fact and agents or any of them, or their or his (or her) substitute or substitutes, may lawfully do or cause to
  be done by virtue hereof.
  Pursuant to the requirements
  of the Securities Act, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated
  on December 19, 2024.
  Name
  Title
  /s/ Eric A. Adams
  President, Chief Executive Officer and Director
  Eric A. Adams
  (principal executive officer)
  /s/ Netta Jagpal
  Chief Financial Officer
  Netta Jagpal
  (principal financial officer and principal accounting officer)
  /s/ Janet Grove
  Director
  Janet Grove
  /s/ Bryan Baldasare
  Director
  Bryan Baldasare
  /s/ Andrew Hull
  Director
  Andrew Hull
  /s/ Nicole Lemerond
  Director
  Nicole Lemerond
  II-
  3
  AUTHORIZED REPRESENTATIVE
  Pursuant to the requirements to Section 6(a) of
  the Securities Act of 1933, the undersigned has signed this registration statement solely in the capacity of the duly authorized representative
  of InMed Pharmaceuticals Inc. in the United States on December 19, 2024.
  By:
  /s/ Andrew Hull
  Andrew Hull
  II-
  4